ClinicalTrials.gg
RecruitingNCT07697664MYSTICUpdated Jul 13, 2026

Moving Yourself in Space and Time: MYSTIC

An interventional study of Complex Rhythmic Movement Sequences (CRMS) Sessions in Parkinson's Disease (PD), Alzheimer's Disease (AD) and Related Disorders and Older Adults (60 - 85 Years Old), sponsored by Emory University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Emory University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 years 3 months after the study started (first participant enrolled Mar 2022, registered Jul 2026).
  • Started Mar 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
146th of 1,257
210 · median 36
Started
2022
with 104 others
No phase
586 of 1,650
147 open now
Primary completion
2028-12
later than 296 of 384 live
Registered
1,622nd of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 146th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 105 that started in 2022, is one of 586 with no phase, reaches primary completion later than 296 of the 384 other live ones, and was the 1,622nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

300 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This study is being done to answer the question: Do people with Parkinson's benefit from a new stepping therapy, and how do people with Parkinson's best learn new steps and rhythms set to music? Researchers will also compare individuals with Parkinson's Disease with people with Mild Cognitive Impairment, and with people with neither of these conditions.

The purpose of this study is to identify principles of human-music interactions to establish underlying guiding theories for application to music-based rehabilitation for older populations with neurodegenerative disease, leading to more refined and targeted music-based rhythmic movement therapies.

Read the detailed description

This study aims to analyze the effects of an innovative rehabilitation intervention comprising complex rhythmic movement sequence (CRMS) rehabilitation (aka, Spatiotemporal Activity Modification (STEAM)) training for adults. The central hypothesis is that the spatial and temporal components of CRMS are learned at slower rates in mild cognitive impairment (MCI) than in controls, and that CRMS-based rehabilitation strategies can improve cognitive and mobility status in MCI. Researchers hypothesize that people with cognitive impairment or Parkinson's disease (PD) will show reduced capacity and slower responses when modulating their movements to auditory cues encoded within complex musical-rhythmic patterns.

Musical rhythm, which includes the timing and pattern of sound in music, can be communicated through touch or via audible cues.

Objective 1: Evaluate the hypothesis that people with cognitive impairment or Parkinson's disease (PD) will show reduced capacity and slower responses when modulating their movements to auditory cues encoded within complex musical-rhythmic patterns.

Aim 1. Determine whether the temporal and spatial components of movement are learned at different timescales during human-music movement sequence learning.

Researchers will draw on research in music theory to develop a novel, task-specific set of musical patterns that map and facilitate learning of complex spatiotemporal rhythms during walking tasks. The research team will measure spatial, temporal, and kinematic variables during the physical human-music interaction and will alter combinations of spatial and temporal relationships within movements, in healthy younger (18-35 years), a subset of whom (n=10) are experienced dancers, and individuals (age older than 50 years), individuals with MCI, and individuals with PD. Researchers will analyze data from single-session time courses of learning rhythm, within-session changes, and short-term (24-hour) retention.

Hypothesis: Compared to healthy older adults and younger adults, older adults with MCI and older adults with PD will show (H1a) smaller magnitude and slower learning rates for spatial and temporal movement components, and (H1b) greater challenge with learning-coupled spatio-temporal (more complex) rhythmic movements versus spatial or temporal rhythmic movement components alone. Data from the subset of experienced dancers will help us establish biomechanical markers of expert performance.

Objective 2: Evaluate the preliminary effects, safety, acceptability, and tolerability of rhythmic movement training in healthy younger adults, healthy older adults, older adults with mild cognitive impairment, and older adults with Parkinson's disease.

Aim 2: Explore the thoughts, perceptions, and attitudes of people with MCI and their caregivers, regarding their relationship to music, to dance, and a therapeutic program involving popular music, rhythm, and movement sequences designed for people with MCI.

Aim 2 Approach: Participants with MCI will be interviewed for their thoughts, perceptions, and attitudes regarding CRMS.

Aim 3: Evaluate the feasibility and preliminary effects of a 3-week daily (e.g., 3-5 times per week; 1.5-hour classes) program of varied rhythmic movement sequences performed to music for people with MCI and people with PD.

Researchers will also assess participants before and after the program for clinical, biomechanical, functional, and cognitive measures. Intensive programs have previously been shown to be feasible and effective for similar forms of training and will allow efficient collection of data as well as testing of a useful schedule of treatment.

03

Conditions studied

  • Parkinson's Disease (PD)
  • Alzheimer's Disease (AD) and Related Disorders
  • Older Adults (60 - 85 Years Old)

Keywords

  • Dance
  • Music
  • Therapy
  • Rehabilitation
  • Neurodegenerative
  • Parkinson's
  • Alzheimer's
  • Motor learning
  • Motor control
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion Criteria for Young adults and adults with normal cognition (NC):

  • 18 to 35 Years old
  • (MoCA) score of 26 to 30

Inclusion criteria

Inclusion Criteria for Older Adults:

  • 50 to 79 with or without MCI
  • 50 to 79 years old with Parkinson's disease (PD), who do NOT have impaired decision-making capacity
  • Participants who achieve less than 150 minutes moderate or 75 minutes vigorous aerobic activity per week (as per the US Department of Health and Human Services (HHS)),

Exclusion criteria

Exclusion Criteria for all groups:

  • Acute medical illness requiring hospitalization;
  • Uncontrolled congestive heart failure;
  • History of stroke in the past three years;
  • Inability to perform study procedures;
  • Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity);
  • On medications that could adversely affect cognition, e.g., antipsychotics, opioids, stimulants, chemotherapy, and neurologic prescriptions to treat Multiple Sclerosis. When applicable, enrollment will be delayed until dosages are stable on e.g., Aricept, Namenda, anticholinesterase inhibitors, for at least 3 months
  • Psychotic disorders
  • Confounding neurologic conditions [e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness >30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae]
  • Substance Use Disorder, Major Depressive Disorder, and Generalized Anxiety Disorder within six months of evaluation.
  • Inability to provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Older adults with MCI

    Participants will attend daily (3-5 times/week) lessons that will last 1.5h for a month (e.g., 3-5 weeks) and will receive contact and monitoring from study staff. The Principal Investigator will monitor fidelity via weekly reports from interventionists.

    Other: Complex Rhythmic Movement Sequences (CRMS) Sessions

  • Active comparator
    Older adults without MCI

    Participants will attend daily (3-5 times/week) lessons that will last 1.5h for a month (e.g., 3-5 weeks) and will receive contact and monitoring from study staff. The Principal Investigator will monitor fidelity via weekly reports from interventionists.

    Other: Complex Rhythmic Movement Sequences (CRMS) Sessions

  • Experimental
    Older adults with PD

    Participants will attend daily (3-5 times/week) lessons that will last 1.5 h for a month (e.g., 3-5 weeks) and will receive contact and monitoring from study staff. The Principal Investigator will monitor fidelity via weekly reports from interventionists.

    Other: Complex Rhythmic Movement Sequences (CRMS) Sessions

  • Active comparator
    Young adults and adults with normal cognition (NC)

    Participants will attend daily (3-5 times/week) lessons that will last 1.5h for a month (e.g., 3-5 weeks) and will receive contact and monitoring from study staff. The Principal Investigator will monitor fidelity via weekly reports from interventionists.

    Other: Complex Rhythmic Movement Sequences (CRMS) Sessions

Interventions

  • OtherComplex Rhythmic Movement Sequences (CRMS) Sessions

    Researchers will establish complex rhythmic movement sequences (CRMS) as an experimental paradigm to identify spatial and temporal components and learning time courses of complex rhythmic movement. Participants will dance with new partners every 15-20 minutes, a widely practiced method of the dance community to enhance learning. The class format is: 1. practicing previously learned steps 2. 25-minute warmup, partnering/rhythmic exercises 3. learning new steps 4. combining old and new steps 5. cool down Participants dance both leading and following roles, learn how to interpret motor goals through touch, and perform activities to foster understanding of the temporal relationship of movement to music.

    Also known as: Spatiotemporal activity modification (STEAM)

06

What researchers measure

Primary outcomes

  1. Four-Square Step Test (FSST)

    The Four Square Step Test (FSST) assesses mechanisms underlying motor-cognitive integration. FSST requires participants to step clockwise, then counterclockwise, into four squares created by rods arranged on the ground in a cross. Participants are instructed to perform FSST "as quickly and as safely as you can," not to touch the rods, and to make both feet contact the floor in each square. Timing begins when the participant initiates movement and stops when both feet are back in the starting square after completing the sequence. Trials will be repeated if the participant does not understand the instructions, fails to complete the sequence accurately, loses balance, or touches a rod. Three successful trials will be recorded, and the fastest time selected for analysis. Lower scores are better.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  2. Gait Speed

    Gait speed testing (Forward/Backwards/Fast): How quickly a person can walk within a specific distance forward and Backwards using GAITRite. GAITRite is a pressure-sensitive walkway that can assess gait anomalies. Lower scores are better.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  3. Body Position Spatial Task (BPST)

    Body Position Spatial Task (BPST) is a validated visuospatial memory task. The BPST incorporates spatial memory and navigational skills while maintaining posture. The examiner verbally and visually shows a series of side, forward, and turning steps, which the examinee repeats. If the examinee repeats the entire pattern correctly, they are scored as 1; any incorrect parts of the pattern result in a score of 0. Participants complete up to 8 different sequences and have up to 2 tries to perform the sequence correctly. Total scores can range from 0 to 8, with higher values indicating more sequences correctly performed and better.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  4. 30-Second Sit-to-Stand test

    The number of sit-to-stand maneuvers completed in 30 seconds is used to measure leg strength and endurance. A higher score is better.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  5. 360 Turn Test (Steps)

    The number of steps the participant takes to turn around in a complete circle. Lower number of steps is better.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  6. 360 Turn Test (Time)

    The time it takes the participants to turn around in a complete circle. Lower times are better.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

Secondary outcomes

  1. Timed Up and Go Simple and Dual tasks (TUG, TUG Cognitive and TUG Manual)

    Measures the time it takes to rise from a chair, walk 3 meters, turn around, and return to the chair in the simple condition. In the Cognitive condition, one is required to simultaneously count backward by 3s from a number between 20 and 100; in the Manual condition, one is required to simultaneously pick up a cup of water and carry it while completing the task. A lower score is a better outcome.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  2. Short Form 12-Quality of Life (SF12)

    The SF12 evaluates the level of activity and perceived physical and mental quality of life. The SF-12 uses a standardized system with scores ranging from 0 to 100, where the general population's average is 50, with higher scores indicating better health. Because it measures relative deviation, the numbers represent the following health levels: Above 50: Better than average health. Exactly 50: Average health status. 40 to 50: Below average health (mild disability or impairment). 30 to 40: Moderate disability or impairment. Below 40: Severe impairment or disability.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  3. Activities-specific Balance Confidence Scale (ABC)

    The Activities-specific Balance Confidence (ABC) Scale is a 16-item self-report questionnaire used to measure an individual's confidence in performing daily activities without losing their balance or feeling unsteady. Participants rate their self-confidence on a percentage scale from 0% (no confidence) to 100% (completely confident) for 16 specific tasks. The total score is added for all 16 items and divided by 16 to get the average percentage score. ≥ 80%: Indicates a high level of physical functioning and balance confidence. 50% to 80%: Indicates a moderate level of physical functioning. \< 50%: Indicates a low level of physical functioning. Higher scores indicate a higher level of functioning and a lower risk of falling, while lower scores (below 67%) often indicate a higher risk of falling.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

Other outcomes

  1. Beck Depression Inventory II (BDI-II)

    The BDI-II is a 21-item self-report measure that taps major depression symptoms according to diagnostic criteria listed in the Diagnostic and Statistical Manual for Mental Disorders. Each item is scored 0-3, and clinicians sum all 21 scores to calculate a total between 0 and 63. Items are summed to create a total score, with lower scores indicating a lower level of depression and higher scores indicating higher levels of depression. Total BDI-II scores are generally interpreted using these cutoff ranges: 0 to 13: Minimal depression 14 to 19: Mild depression 20 to 28: Moderate depression 29 to 63: Severe depression

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  2. Physical Activity Scale for the Elderly (PASE)

    The PASE score combines information on leisure, household, and occupational activity. The PASE assesses the types of activities typically chosen by older adults (walking, recreational activities, exercise, housework, yard work, and caring for others. It uses frequency, duration, and intensity level of activity over the previous week to assign a score, ranging from 0 to 793, with higher scores indicating greater physical activity.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  3. Multidimensional Scale of Perceived Social Support (MSPSS) Score

    The MSPSS has 12 items that assess how social support factors are perceived by individuals. This scale has three subscales to evaluate support by family, friends, and significant others. Respondents rate statements on a scale of 1 (very strongly disagree) to 7 (very strongly agree). Total scores range from 12 to 84, with higher scores being better and indicating an increased perception of social support.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  4. Patient Health Questionnaire (PHQ-9) Score

    The Patient Health Questionnaire (PHQ-9) is a 9-item, validated measure of depression severity in dementia. Respondents indicate how bothered by problems they are on a scale from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 27, where higher scores indicate more severe depression. Scores fall into bands: 0 to 4 (none), 5 to 9 (mild), 10 to 14 (moderate), 15 to 19 (moderately severe), and 20 to 27 (severe)

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  5. Clinical Dementia Rating (CDR) Questionnaire Score

    The CDR is designed to reflect the level of cognitive impairment based on a semi-structured interview with an informant and a separate mental status exam with the patient. The clinician rates each of the six general domains involving memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care. A global rating is then generated, ranging from 0 = no impairment to 3 = severe impairment. Lower scores=better outcome. 0: Normal 0.5: Very Mild Dementia 1. Mild Dementia 2. Moderate Dementia 3. Severe Dementia

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  6. 6 Minute Walk Test (6MWT) Distance

    The 6-minute walk test (6MWT) assesses distance, in meters, walked over 6 minutes as a sub-maximal test of aerobic capacity and endurance. A higher score indicates a better outcome. Normal range: A healthy adult typically walks between 400 m and 700 m in 6 minutes. Impaired capacity: Walking less than 350 m to 300 m is associated with a poor prognosis and indicates significantly reduced functional capacity in conditions like chronic obstructive pulmonary disease (COPD) or heart failure. Improvement: An increase in your distance by ≥ 30 m overtime typically indicates a positive response to treatment.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  7. Arterial stiffness (pulse wave activity)

    Pulse wave activity (PWA) will be used to measure the arterial stiffness and will be measured using a SphygmoCor system before and after the intervention. A lower PWA(slower speed) indicates healthy, flexible arteries, whereas a higher PWA (faster speed) indicates stiff, less elastic arteries.

    Time frame: Baseline and post-intervention (3 to 5 weeks)

  8. Participants' Satisfaction of the intervention (Acceptability)

    Satisfaction will be assessed post-intervention only with an Exit Questionnaire with two focus groups, balanced for gender and race. Participants will rate (extremely easy/very easy) and their overall satisfaction with the intervention. A higher score indicates better satisfaction.

    Time frame: Post-intervention (3 to 5 weeks)

  9. Number of Participants Retained in Each Group

    Number of participants (Retention rate) retained in each group after enrollment throughout study participation.

    Time frame: Post-intervention (3 to 5 weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Dec 2028, 81 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 81 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 13, 2026
StartActual
Mar 25, 2022
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07697664
Lead sponsor
Emory University
Responsible party
Madeleine Eve Hackney (Associate Professor, Emory University School of Medicine, Emory University) — Principal investigator
First posted
Jul 13, 2026
Start date
Mar 25, 2022
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 13, 2026

Study contacts

Madeleine E. Hackney, PhD
Contact
mehackn@emory.edu
314-412-4852
Madeleine E. Hackney, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion